Evidence map›Paper›PMID 42524362›Full record

ArticleCase reports in oncology

Efficacy of Pazopanib for a Patient with

Yurina Ochiai, Saori Hayashi, Emiko Hiraoka, Takafumi Morisaki, Yoshiki Otsubo, Chiaki Nakahara, Yo Sato, Kimihisa Mizoguchi, Yuichi Hisamatsu, Mamoru Ito and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yurina OchiaiDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Saori HayashiDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Emiko HiraokaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Takafumi MorisakiDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Yoshiki OtsuboDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Chiaki NakaharaDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Yo SatoDepartment of Clinical and Oncological Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kimihisa MizoguchiDepartment of Clinical and Oncological Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yuichi HisamatsuDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Natsuko OkitaClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
Makoto KuboDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fibroblast growth factor receptor 1 ( Case Presentation: A 71-year-old woman was diagnosed with bilateral luminal-HER2 type breast cancer (pT2N1M0) 18 years previously, and underwent bilateral mastectomy and axillary lymph nodes dissection followed by adjuvant therapy. She had no family history. She developed bone and liver metastases 4 years after the operation and her condition became worse, despite multiple lines of endocrine and cytotoxic therapies. She was treated with pazopanib under the trial because comprehensive genomic profiling showed Conclusion: Pazopanib is likely to have a clinical benefit for patients with

Indexed as

FGFR1 amplificationGenomic profilingMetastatic breast cancerOff-label therapyPazopanib

Identifiers

PMID42524362
PMCPMC13412246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.